Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

41.68
+1.202.96%
Volume:209.23K
Turnover:8.67M
Market Cap:4.53B
PE:-22.53
High:41.94
Open:41.01
Low:40.42
Close:40.48
52wk High:48.51
52wk Low:14.25
Shares:108.60M
Float Shares:88.17M
Volume Ratio:0.42
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8502
EPS(LYR):-1.6302
ROE:-38.03%
ROA:-25.03%
PB:10.10
PE(LYR):-25.57

Loading ...

Edgewise Therapeutics is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Aug 12

Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs

TIPRANKS
·
Aug 11

Wedbush Adjusts Pt on Edgewise Therapeutics to $53 From $52, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Edgewise Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate

Benzinga Earnings
·
Aug 06

Edgewise Therapeutics Q2 Operating Income USD -61.943 Million

Reuters
·
Aug 06

Edgewise Net Loss Widens 58.74% to $57.33 Million in Q2 FY26

Reuters
·
Aug 06

Edgewise Therapeutics Q2 Operating Expenses USD 61.943 Million

THOMSON REUTERS
·
Aug 06

Edgewise Therapeutics Q2 Basic EPS USD -0.53

THOMSON REUTERS
·
Aug 06

Press Release: Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 06

Edgewise’s EDG-15400 Phase 1 Milestone: What It Means for EWTX Investors

TIPRANKS
·
Aug 06

Edgewise Therapeutics is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jul 20

Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI

TIPRANKS
·
Jul 20

Edgewise Therapeutics Files Amended 8-K with Unaudited Pro Forma Financials for Servier Asset Sale

Reuters
·
Jul 16

Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier

TIPRANKS
·
Jul 14

Edgewise Therapeutics Sells Sevasemten, Muscular Dystrophy Business to Servier for up to $2.65 Billion

Reuters
·
Jul 13

Edgewise Therapeutics completes sale of sevasemten for up to $2.65B

TIPRANKS
·
Jul 13

Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4

TIPRANKS
·
Jul 13

Edgewise Therapeutics Completes Sale of Sevasemten for up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

THOMSON REUTERS
·
Jul 13

Edgewise Therapeutics' EDG-7500 Seen Entering 'Catalyst-Dense' Regulatory Period, Oppenheimer Says

MT Newswires Live
·
Jul 09